Peripheral blood cells chimerism after unrelated cord blood transplantation in children: kinetics, predictive factors and impact on post-transplant outcome

Br J Haematol. 2014 Aug;166(4):557-65. doi: 10.1111/bjh.12918. Epub 2014 Apr 29.

Abstract

This study aimed to describe kinetics of complete donor chimerism occurrence (cDC, >99·9% donor) after unrelated cord blood transplantation (UCBT), to identify its predictive factors and its impact on post-transplant outcome. Ninety-four children who received single UCBT after a myeloablative conditioning regimen had blood chimerism evaluation at predefined post-transplant dates, using a real-time polymerase chain reaction method with 0·1% sensitivity. Cumulative incidence of cDC at 1 year post-transplantation was 61·8%. Three predictive factors were identified in multivariate analysis: history of malignant disease (P = 0·03), older age (above 2·16 years, the first quartile of age, P = 0·0055) and higher level of cord/recipient human leucocyte antigen mismatch (4/6 vs. 5-6/6, P < 0·001) increased the probability of post-transplant cDC. Although graft cell dose had a strong impact on haematological recovery, it did not apparently influence cDC occurrence. Early cDC (i.e. more than 99·9% donor chimerism on days 15-30 post-transplant) appeared useful to predict engraftment (P = 0·003) as well as acute and chronic graft-versus-host disease (GvHD). Severe acute or chronic GvHD never occurred in patients with DC ≤99·9%, suggesting than even minimal residual host haematopoiesis is associated with a very low risk of GvHD after UCBT.

Keywords: childhood; chimerism; graft-versus-host disease; human leucocyte antigen compatibilty; unrelated cord blood transplantation.

MeSH terms

  • Adolescent
  • Allografts / physiology
  • Child
  • Child, Preschool
  • Cord Blood Stem Cell Transplantation / adverse effects*
  • Female
  • Graft vs Host Disease / etiology
  • Hematopoiesis / physiology
  • Humans
  • Infant
  • Male
  • Minor Histocompatibility Antigens
  • Prospective Studies
  • Transplantation Chimera / physiology*
  • Transplantation Conditioning / methods
  • Transplantation, Homologous
  • Treatment Outcome

Substances

  • Minor Histocompatibility Antigens